ReviewEJNMMI radiopharmacy and chemistry2019
[
Review in EJNMMI radiopharmacy and chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- Automated Synthesis of Radiopharmaceuticals: Technology, Applications, and Regulatory Perspectives.Nuclear medicine and molecular imaging · 2026Review
- Ionic Liquid Aided [ChemistryOpen · 2025Article
- Carbon isotopic labelling of carboxylic acids enabled by organic photoredox-catalysed cyanation.Nature synthesis · 2025Article
- Automated production ofJournal of labelled compounds & radiopharmaceuticals · 2024Article
- Copper(I)-free syntheses of [Chemical communications (Cambridge, England) · 2024Article
- Gas Phase Transformations in Carbon-11 Chemistry.International journal of molecular sciences · 2024Review
- Intranasal delivery of imaging agents to the brain.Theranostics · 2024Review
- Automated Synthesis of [Current radiopharmaceuticals · 2024Article
- Development and Optimization ofACS pharmacology & translational science · 2023Review
- Core-Labeling (Radio) Synthesis of Phenols.Organic letters · 2023Article
- Unlocking full and fast conversion in photocatalytic carbon dioxide reduction for applications in radio-carbonylation.Nature communications · 2023Article
- Reactive Palladium-Ligand Complexes forPharmaceuticals (Basel, Switzerland) · 2023Review
- Recent Developments in Carbon-11 Chemistry and Applications for First-In-Human PET Studies.Molecules (Basel, Switzerland) · 2023Review
- Ring-opening of non-activated aziridines with [RSC advances · 2022Article
- Strategic, feasibility, economic, and cultural aspects of phase 0 approaches: Is it time to change the drug development process in order to increase productivity?Clinical and translational science · 2022Review
- Recyclable cooperative catalyst for accelerated hydroaminomethylation of hindered amines in a continuous segmented flow reactor.Nature communications · 2022Article
- PET Molecular Imaging in Drug Development: The Imaging and Chemistry Perspective.Frontiers in medicine · 2022Review
- Broad Scope and High-Yield Access to Unsymmetrical Acyclic [Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- Radiosynthesis of [Frontiers in nuclear medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.